Rankings / Weight Loss — Incretins & Amylin
Cagrilintide
Weight loss · Amylin analog
Tier B
What this is
REDEFINE 1 (Garvey NEJM 2025): CagriSema 2.4mg/2.4mg achieved -20.4% body weight at 68 weeks vs -3.0% placebo (n=3417, no T2D). Notably below the ~25% projected from Phase 2 — Novo stock fell at the December 2024 readout. Cagrilintide alone -11.5%. REDEFINE 2 (T2D, n=1206): -13.7% vs -3.4% placebo at 68 weeks. REDEFINE 1 BP analysis (Hypertension 2025): -10.9 mmHg SBP. Falls slightly short of tirzepatide 15mg (-22.5% in SURMOUNT-1); head-to-head not yet done.
Mechanism
Long-acting amylin analog; reduces gastric emptying and food intake via CGRP/amylin receptors in brainstem; synergistic with GLP-1 agonists
Dose & route
2.4 mg SC weekly (monotherapy); CagriSema = cagrilintide 2.4 mg + semaglutide 2.4 mg combo SC weekly
Citations
- https://doi.org/10.1056/NEJMoa2502081
- https://doi.org/10.1056/NEJMoa2502082
- https://doi.org/10.1161/HYPERTENSIONAHA.125.26055
- https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01751-7/fulltext
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.